Announcement

Collapse
No announcement yet.

STUDY: Endovascular treatment of CCSVI in patients with MS: 462 clinical outcomes

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • STUDY: Endovascular treatment of CCSVI in patients with MS: 462 clinical outcomes

    Source: Neurol Sci

    Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases
    Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G,

    The MS Study Group-Italian Society of Neurology; Neurological Sciences (Jan 2013)

    Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of the study is to evaluate the outcome and safety of ET in Italian MS patients. Italian MS centers that are part of the Italian MS Study Group were all invited to participate to this retrospective study. A structured questionnaire was used to collect detailed clinical data before and after the ET. Data from 462 patients were collected in 33 centers. ET consisted of balloon dilatation (93 % of cases) or stent application. The mean follow-up duration after ET was 31 weeks. Mean EDSS remained unchanged after ET (5.2 vs. 4.9), 144 relapses occurred in 98/462 cases (21 %), mainly in RR-MS patients. Fifteen severe adverse events were recorded in 3.2 % of cases. Given the risk of severe adverse events and the lack of objective beneficial effects, our findings confirm that at present ET should not be recommended to patients with MS.
    Dave Bexfield
    ActiveMSers
Working...
X